| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Jens Juul Holst | Q28373106 |
| Carolyn F. Deacon | Q55446060 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | type 2 diabetes | Q3025883 |
| P304 | page(s) | 488-499 | |
| P577 | publication date | 2009-05-14 | |
| P1433 | published in | Advances in Therapy | Q4686392 |
| P1476 | title | Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes | |
| P478 | volume | 26 |
| Q37965612 | A review of gliptins in 2011. |
| Q83226453 | Are sulfonylureas less desirable than DPP-4 inhibitors as add-on to metformin in the treatment of type 2 diabetes? |
| Q35998458 | Association of DPP4 Gene Polymorphisms with Type 2 Diabetes Mellitus in Malaysian Subjects |
| Q59487668 | Bioequivalence of Saxagliptin/Metformin Extended-Release (XR) Fixed-Dose Combination Tablets and Single-Component Saxagliptin and Metformin XR Tablets in Healthy Adult Chinese Subjects |
| Q37767398 | Can therapies that target the incretin system improve our ability to treat type 2 diabetes? |
| Q38017726 | Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors |
| Q47370187 | Construction of a novel vaccine by conjugating a B-cell epitope of DPP4 to peptide IA2(5)-P2-1 to significantly control type 1 diabetes in NOD mice |
| Q27028127 | DPP-4 inhibition and islet function |
| Q93234592 | DPP4 inhibition: preventing SARS-CoV-2 infection and/or progression of COVID-19? |
| Q48015498 | Dapagliflozin/Saxagliptin Fixed-Dose Tablets: A New Sodium-Glucose Cotransporter 2 and Dipeptidyl Peptidase 4 Combination for the Treatment of Type 2 Diabetes |
| Q36395003 | Dipeptidyl peptidase 4 promotes epithelial cell transformation and breast tumourigenesis via induction of PIN1 gene expression |
| Q37735838 | Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus |
| Q38200670 | Dipeptidyl peptidase-4 inhibitors: pharmacokinetics, efficacy, tolerability and safety in renal impairment. |
| Q37778379 | Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions |
| Q33794098 | GLP-1 for type 2 diabetes |
| Q38152405 | Head-to-head comparison of dipeptidyl peptidase-IV inhibitors and sulfonylureas - a meta-analysis from randomized clinical trials |
| Q37760515 | Incretin-based therapies for type 2 diabetes mellitus: current status and future prospects |
| Q37316259 | Incretin-based therapies: new treatments for type 2 diabetes in the new millennium. |
| Q37845218 | Is the GLP-1 system a viable therapeutic target for weight reduction? |
| Q37890779 | Linagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus |
| Q37661427 | Medicinal Chemistry of Incretin Mimetics and DPP-4 Inhibitors |
| Q42058426 | New treatments in the management of type 2 diabetes: a critical appraisal of saxagliptin |
| Q24569706 | Nitrile-containing pharmaceuticals: efficacious roles of the nitrile pharmacophore |
| Q38582135 | Peptide Vaccines for Hypertension and Diabetes Mellitus |
| Q38470357 | Pharmacokinetic study of saxagliptin in healthy Chinese subjects |
| Q34219918 | Potency, selectivity and prolonged binding of saxagliptin to DPP4: maintenance of DPP4 inhibition by saxagliptin in vitro and ex vivo when compared to a rapidly-dissociating DPP4 inhibitor |
| Q34135843 | Protein Tyrosine Phosphatase 1B Inhibitors: A Molecular Level Legitimate Approach for the Management of Diabetes Mellitus |
| Q28081569 | Recent Advances in Dipeptidyl-Peptidase-4 Inhibition Therapy: Lessons from the Bench and Clinical Trials |
| Q35411329 | Saxagliptin: A dipeptidyl peptidase-4 inhibitor in the treatment of type 2 diabetes mellitus |
| Q34229975 | Sex differences in type 2 diabetes: focus on disease course and outcomes |
| Q33866808 | The evolving place of incretin-based therapies in type 2 diabetes |
| Q37687552 | Therapeutic vaccine against DPP4 improves glucose metabolism in mice |
| Q38058568 | Use of the dipeptidyl peptidase-4 inhibitor linagliptin in combination therapy for type 2 diabetes |
Search more.